Precision Business Insights

Portfolio

Research Reports

SELECT LICENSE TYPE
Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner

Why Precision Business Insights?

  • Pre and Post Sale Support

    Get in touch with our industry experts to resolve your research queries before and after buying the report. Avail free 60 minutes analyst tele-call to get additional market information before and after purchase

  • Special Pricing and Discounts

    Avail special pricing for the purchase of report sections,regional insights, and historical data. Discounts for government bodies, research institutes, universities, NGO’s and start-up’s

  • In-depth Market Analysis

    Our research reports provides holistic market information with 360 degree analysis. We adopt 3 pronged strategy to analyze the market i.e. Secondary research , primary research, and expert validation

  • Accurate and Reliable Market Data

    Utmost focus on delivering accurate and reliable research reports. We adopt internally developed data mining tools to eliminate any data errors

  • NICHE AND GROWTH MARKETS EXPERTISE

    Proven expertise in delivering new and emerging markets product and technology advancements. We provide market information across the developed and emerging markets

  • ADHERING TO QUICK DELIVERY TIME LINES

    We provide impeccable research reports in quick turnaround time

Canine Leishmaniasis Management Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024


 

Available formats:    

StumbleUponEmail

Global Canine Leishmaniasis Management Market

 

Canine leishmaniasis is a vector-borne disease caused by the Leishmania infantum and Leishmania chagasi. Canine leishmaniasis is transmitted through the infected Phlebotominae flies. The severity of the canine leishmaniasis leads to the death of animals and high risk of disease transmission in humans and other dogs.  The primary symptoms associated with the canine leishmaniasis include asthenia, anaemia, cachexia, weight loss, skin lesions, and muscular atrophy. In the later stage the symptoms like abnormal growth of nails, conjunctivitis, and renal failure may occur in the canines. The canine leishmaniasis can be prevented by administering the vaccines initially 3 doses with 3-week interval between them and an annual dose which increase the immunity in the canines.

 

The canine leishmaniasis management market is growing at a significant CAGR due to increase in adoption of canines. A rise in the prevalence of canine Leishmania, increase in the research and development for new vaccines for canine leishmaniasis management, rise in the expenditure for animal welfare and wellness, and patent filings for the various canine leishmaniasis management formulations might fuel the canine leishmaniasis management market over the forecast years. However, stringent regulatory policies for the approval of new vaccines for the canine leishmaniasis management, storage of vaccines, lack of awareness regarding canine leishmaniasis management, increase in the canine culling process, and dearth of canine leishmaniasis management products in the market might hamper the canine leishmaniasis management market growth in the forecast years.

 

Canine Leishmaniasis Management Market

Canine Leishmaniasis Management Market

 

Canine leishmaniasis management market is segmented on the basis of product type, disease type, route of administration, and end user

 

Based on the product type, canine leishmaniasis management market is segmented into the following:

  • Canine leishmaniasis prevention
    • Vaccines
  • Canine leishmaniasis treatment
    • Antibiotics
    • Polyene antibiotics (Amphotericin B)
    • Marbofloxacin
    • Others
    • Miltefosine
    • Meglumine antimoniate
    • Pentavalent antimonials
    • Allopurinol combinations
    • Paromomycin
    • Others

 

Based on the disease type, canine leishmaniasis management market is segmented into the following:

  • Visceral leishmaniasis
  • Cutaneous leishmaniasis
  • Mucocutaneous leishmaniasis

 

Based on the route of administration, canine leishmaniasis management market is segmented into the following:

  • Oral
  • Parenteral
  • Topical

 

Based on the distribution channel, canine leishmaniasis management market is segmented into the following:

  • Veterinary clinics
  • Veterinary pharmacies
  • Online pharmacies
  • NGO’s
  • Others

 

Global canine leishmaniasis management market is in the developing stage with several international players are actively involved in the development of formulations for the treatment and prevention of canine leishmaniasis. Increase in the research and development for canine leishmaniasis vaccines, product approval from various regulatory bodies such as EMEA and FDA, and launching of new products into the market might fuel the canine leishmaniasis management market over the forecast period. For instance, in March 2011, EMEA approved the marketing authorization in the Europe region for CaniLeish vaccine manufactured by Virbac S.A. Similarly, US Food and Drug Administration scientists are working with India and Brazil scientists for the development of a non-virulent vaccine to treat visceral leishmaniasis in canines.

 

Geographically, canine leishmaniasis management market is segmented into the following regions Viz. Europe, North America, Asia Pacific, Middle East and Africa, and Latin America.  Europe holds significant share in the global canine leishmaniasis management market owing to the presence of tropical and subtropical areas which are favourable for the growth of sand flies. Spain, France, Greece, Italy and some other European countries have the highest prevalence of canine leishmaniasis. Increase in the research and development for Leishmania vaccines, rise in the expenditure of animal welfare and growing awareness about the canine leishmaniasis treatment might bolster the market. Asia Pacific canine leishmania management market growth over the forecast years attributed to poor hygienic conditions in the rural area, increase in the canine adoption rate, and the environmental conditions that favour the growth of sand flies. Increase in the canine leishmaniasis prevalence rate majorly in India, China, Bangladesh, Saudi Arabia, and UAE might fuel the canine leishmaniasis management market. North America holds a reasonable share due to increase in the adoption rate of canines (according to American Pet Products Association, approximately 78 Mn canines were owned in the U.S.).

 

Some of the players in canine leishmaniasis management market are Zoetis, Inc. (Pfizer) (U.S), Hertape Calier Saude Animal S.A. (Brazil), Virbac AH Inc. (France), Laboratories Leti (Spain), Bioiberica S.A. (Spain), and Sanofi S.A. (France) to name a few.

  • In September 2016, European commission authorized the marketing of Letifend vaccine manufactured by Laboratories Leti to treat canine leishmaniasis

 

Report Outline:

  • The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
  • The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments, and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

1. Executive Summary
 
2. Global Canine Leishmaniasis Management Market Introduction
2.1. Global Canine Leishmaniasis Management Market– Taxonomy
2.2. Global Canine Leishmaniasis Management Market–Definitions
2.2.1. Product Type
2.2.2. Disease Type
 
3. Global Canine Leishmaniasis Management Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Canine Leishmaniasis Management Market Dynamics – Factors Impact Analysis
3.6. Global Canine Leishmaniasis Management Market– Recent Market Introductions
 
4. Global Canine Leishmaniasis Management Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
 
5. Global Canine Leishmaniasis Management Market Forecast, By Product Type, 2013 – 2017 and Forecast, 2018 – 2024
5.1. Vaccines
5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Antibiotics
5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Miltefosine
5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Meglumine Antimoniate
5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Pentavalent Antimonials
5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Allopurinol Combinations
5.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Paromomycin
5.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Others
5.8.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
 
6. Global Canine Leishmaniasis Management Market Forecast, By Disease Type, 2013 – 2017 and Forecast, 2018 – 2024
6.1. Visceral Leishmaniasis
6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Cutaneous Leishmaniasis
6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Mucocutaneous Leishmaniasis
6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
 
7. Global Canine Leishmaniasis Management Market Forecast, By Route of Administration, 2013 – 2017 and Forecast, 2018 – 2024
7.1. Oral
7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Parenteral
7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Topical
7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
 
8. Global Canine Leishmaniasis Management Market Forecast, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024
8.1. Veterinary clinics
8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Veterinary pharmacies
8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online pharmacies
8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. NGO’s
8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Others
8.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
 
9. Global Canine Leishmaniasis Management Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024
9.1. North America
9.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Canine Leishmaniasis Management Market- Opportunity Analysis Index – By Disease Type, By Product Type, By Route of Administration, By Distribution Channel, and Region, 2018 – 2024
 
10. North America Canine Leishmaniasis Management Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
10.1. Product Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.1. Canine Leishmaniasis Prevention
10.1.1.1. Vaccines
10.1.2. Canine Leishmaniasis Treatment
10.1.3. Antibiotics
10.1.3.1. Polyene Antibiotics (Amphotericin B)
10.1.3.2. Marbofloxacin
10.1.3.3. Others
10.1.4. Miltefosine
10.1.5. Meglumine Antimoniate
10.1.6. Pentavalent Antimonials
10.1.7. Allopurinol Combinations
10.1.8. Paromomycin
10.1.9. Others
10.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Visceral Leishmaniasis
10.2.2. Cutaneous Leishmaniasis
10.2.3. Mucocutaneous Leishmaniasis
10.3. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Oral
10.3.2. Parenteral
10.3.3. Topical
10.4. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Veterinary Clinics
10.4.2. Veterinary Pharmacies
10.4.3. Online Pharmacies
10.4.4. NGO’s
10.4.5. Others
10.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Canine Leishmaniasis Management Market- Opportunity Analysis Index – By Disease Type, By Product Type, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
10.7. North America Canine Leishmaniasis Management Market Dynamics – Trends
 
11. Europe Canine Leishmaniasis Management Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
11.1. Product Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.1. Canine Leishmaniasis Prevention
11.1.1.1. Vaccines
11.1.2. Canine Leishmaniasis Treatment
11.1.3. Antibiotics
11.1.3.1. Polyene Antibiotics (Amphotericin B)
11.1.3.2. Marbofloxacin
11.1.3.3. Others
11.1.4. Miltefosine
11.1.5. Meglumine Antimoniate
11.1.6. Pentavalent Antimonials
11.1.7. Allopurinol Combinations
11.1.8. Paromomycin
11.1.9. Others
11.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Visceral Leishmaniasis
11.2.2. Cutaneous Leishmaniasis
11.2.3. Mucocutaneous Leishmaniasis
11.3. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Oral
11.3.2. Parenteral
11.3.3. Topical
11.4. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Veterinary Clinics
11.4.2. Veterinary Pharmacies
11.4.3. Online Pharmacies
11.4.4. NGO’s
11.4.5. Others
11.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Canine Leishmaniasis Management Market- Opportunity Analysis Index – By Disease Type, By Product Type, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
11.7. Europe Canine Leishmaniasis Management Market Dynamics – Trends
 
12. Asia-Pacific Canine Leishmaniasis Management Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
12.1. Product Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.1. Canine Leishmaniasis Prevention
12.1.1.1. Vaccines
12.1.2. Canine Leishmaniasis Treatment
12.1.3. Antibiotics
12.1.3.1. Polyene Antibiotics (Amphotericin B)
12.1.3.2. Marbofloxacin
12.1.3.3. Others
12.1.4. Miltefosine
12.1.5. Meglumine Antimoniate
12.1.6. Pentavalent Antimonials
12.1.7. Allopurinol Combinations
12.1.8. Paromomycin
12.1.9. Others
12.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Visceral Leishmaniasis
12.2.2. Cutaneous Leishmaniasis
12.2.3. Mucocutaneous Leishmaniasis
12.3. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Oral
12.3.2. Parenteral
12.3.3. Topical
12.4. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Veterinary Clinics
12.4.2. Veterinary Pharmacies
12.4.3. Online Pharmacies
12.4.4. NGO’s
12.4.5. Others
12.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Canine Leishmaniasis Management Market- Opportunity Analysis Index – By Disease Type, By Product Type, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
12.7. Asia-Pacific Canine Leishmaniasis Management Market Dynamics – Trends
 
13. Latin America Canine Leishmaniasis Management Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
13.1. Product Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.1. Canine Leishmaniasis Prevention
13.1.1.1. Vaccines
13.1.2. Canine Leishmaniasis Treatment
13.1.3. Antibiotics
13.1.3.1. Polyene Antibiotics (Amphotericin B)
13.1.3.2. Marbofloxacin
13.1.3.3. Others
13.1.4. Miltefosine
13.1.5. Meglumine Antimoniate
13.1.6. Pentavalent Antimonials
13.1.7. Allopurinol Combinations
13.1.8. Paromomycin
13.1.9. Others
13.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Visceral Leishmaniasis
13.2.2. Cutaneous Leishmaniasis
13.2.3. Mucocutaneous Leishmaniasis
13.3. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Oral
13.3.2. Parenteral
13.3.3. Topical
13.4. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Veterinary Clinics
13.4.2. Veterinary Pharmacies
13.4.3. Online Pharmacies
13.4.4. NGO’s
13.4.5. Others
13.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Venezuela
13.5.5. Rest of Latin America
13.6. Latin America Canine Leishmaniasis Management Market- Opportunity Analysis Index – By Disease Type, By Product Type, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
13.7. Latin America Canine Leishmaniasis Management Market Dynamics – Trends
 
14. Middle East & Africa Canine Leishmaniasis Management Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
14.1. Product Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.1. Canine Leishmaniasis Prevention
14.1.1.1. Vaccines
14.1.2. Canine Leishmaniasis Treatment
14.1.3. Antibiotics
14.1.3.1. Polyene Antibiotics (Amphotericin B)
14.1.3.2. Marbofloxacin
14.1.3.3. Others
14.1.4. Miltefosine
14.1.5. Meglumine Antimoniate
14.1.6. Pentavalent Antimonials
14.1.7. Allopurinol Combinations
14.1.8. Paromomycin
14.1.9. Others
14.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Visceral Leishmaniasis
14.2.2. Cutaneous Leishmaniasis
14.2.3. Mucocutaneous Leishmaniasis
14.3. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Oral
14.3.2. Parenteral
14.3.3. Topical
14.4. Route of Administration Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Veterinary Clinics
14.4.2. Veterinary Pharmacies
14.4.3. Online Pharmacies
14.4.4. NGO’s
14.4.5. Others
14.5. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Canine Leishmaniasis Management Market- Opportunity Analysis Index – By Disease Type, By Product Type, By Route of Administration, By Distribution Channel, and Country, 2018 – 2024
14.7. MEA Canine Leishmaniasis Management Market Dynamics – Trends
 
15. Competition Landscape
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Zoetis, Inc. (Pfizer) (U.S)
15.2.2. Hertape Calier Saude Animal S.A. (Brazil)
15.2.3. Virbac AH Inc. (France)
15.2.4. Laboratories Leti (Spain)
15.2.5. Bioiberica S.A. (Spain)
 
16. Research Methodology
 
17. Key Assumptions and Acronyms

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Avail Discount  Up To 20%

Need more discount on this report?

Call or e-mail us for:

(U.S.) – +1-866-598-1553

Contact SalesTOLL FREE: +1-866-598-1553